These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 25511544)

  • 1. Case of pure ovarian squamous cell carcinoma resistant to combination chemotherapy with paclitaxel and carboplatin but responsive to monotherapy with weekly irinotecan.
    Nakamura Y; Kamei T; Shinagawa M; Sakamoto Y; Miwa I
    J Obstet Gynaecol Res; 2015 May; 41(5):809-12. PubMed ID: 25511544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A case of rapidly growing ovarian squamous cell carcinoma successfully controlled by weekly paclitaxel-carboplatin administration.
    Ohtani K; Sakamoto H; Masaoka N; Shimada K; Kanaeda T; Kurihara M; Nagai N; Satoh K
    Gynecol Oncol; 2000 Dec; 79(3):515-8. PubMed ID: 11104632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Paclitaxel + carboplatin (TC)-resistant stage Ic squamous cell carcinomas arising in mature cystic teratomas of the ovary].
    Ishikawa M; Nakayama K; Yeasmin S; Katagiri A; Iida K; Nakayama N; Miyazaki K
    Gan To Kagaku Ryoho; 2010 Apr; 37(4):747-52. PubMed ID: 20414041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A case of pure-type ovarian squamous cell carcinoma for which combination chemotherapy consisting of paclitaxel and carboplatin was not effective.
    Todo Y; Minobe S; Sasaki M; Yamamoto R; Sakuragi N
    Gynecol Oncol; 2005 Apr; 97(1):223-7. PubMed ID: 15790463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of combination chemotherapy using docetaxel and irinotecan for TC-refractory or TC-resistant ovarian carcinomas (GOGO-OV2 study) and for primary clear or mucinous ovarian carcinomas (GOGO-OV3 Study).
    Ueda Y; Miyatake T; Nagamatsu M; Yamasaki M; Nishio Y; Yoshino K; Fujita M; Tsutsui T; Enomoto T; Kimura T
    Eur J Obstet Gynecol Reprod Biol; 2013 Sep; 170(1):259-63. PubMed ID: 23880598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ATP-based chemotherapy response assay in primary or recurrent ovarian and peritoneal cancer.
    Lee M; Kim SW; Nam EJ; Cho H; Kim JH; Kim YT; Kim S
    Yonsei Med J; 2014 Nov; 55(6):1664-71. PubMed ID: 25323906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab, Carboplatin and Paclitaxel Combination Treatment in Advanced Stage Ovarian Cancer: The First Experience in Thammasat University Hospital, Thailand: A Case Report.
    Suwannarurk K; Thaweekul Y; Mairaing K; Poomtavorn Y; Tangtiang K; Piyawang W; Bhamarapravatana K
    J Med Assoc Thai; 2015 Apr; 98 Suppl 3():S121-5. PubMed ID: 26387399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary squamous cell carcinoma associated with ovarian endometriosis: a case report and literature review.
    Yamakawa Y; Ushijima M; Kato K
    Int J Clin Oncol; 2011 Dec; 16(6):709-13. PubMed ID: 21301917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma.
    Abaid LN; Micha JP; Rettenmaier MA; Brown JV; Mendivil AA; Lopez KL; Goldstein BH
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):101-7. PubMed ID: 23660691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete response to radiation therapy in a patient with chemotherapy-resistant ovarian clear cell adenocarcinoma.
    Takai N; Utsunomiya H; Kawano Y; Nasu K; Narahara H; Miyakawa I
    Arch Gynecol Obstet; 2002 Dec; 267(2):98-100. PubMed ID: 12439556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer.
    Choong NW; Vokes EE; Haraf DJ; Tothy PK; Ferguson MK; Kasza K; Rudin CM; Hoffman PC; Krauss SA; Szeto L; Mauer AM
    J Thorac Oncol; 2008 Jan; 3(1):59-67. PubMed ID: 18166842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A case of platinum-resistant, recurrent ovarian clear cell adenocarcinoma successfully treated with irinotecan (CPT-11) and paclitaxel (PTX) chemotherapy].
    Konishi H; Takehara K; Okame S; Yamamoto Y; Kojima A; Shiroyama Y; Yokoyama T; Nogawa T
    Gan To Kagaku Ryoho; 2014 Nov; 41(11):1437-9. PubMed ID: 25434451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel/carboplatin as first-line chemotherapy in advanced ovarian cancer: efficacy and adverse effects with special consideration of peripheral neurotoxicity.
    Mayerhofer K; Bodner-Adler B; Bodner K; Leodolter S; Kainz C
    Anticancer Res; 2000; 20(5C):4047-50. PubMed ID: 11268499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group.
    Bamias A; Papadimitriou C; Efstathiou E; Rodolakis A; Vlahos G; Voulgaris Z; Bozas G; Fountzilas G; Aravantinos G; Razis E; Gika D; Dimopoulos MA
    BMC Cancer; 2006 Sep; 6():228. PubMed ID: 16999858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential combination of paclitaxel-carboplatin and paclitaxel-liposomal doxorubicin as a first-line treatment in patients with ovarian cancer. A multicenter phase II trial.
    Potamianou A; Androulakis N; Papakotoulas P; Toufexi H; Latoufis C; Kouroussis C; Christofilakis C; Xenidis N; Georgoulias V; Polyzos A
    Oncology; 2005; 69(4):348-53. PubMed ID: 16293974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel.
    Hoskins P; Vergote I; Cervantes A; Tu D; Stuart G; Zola P; Poveda A; Provencher D; Katsaros D; Ojeda B; Ghatage P; Grimshaw R; Casado A; Elit L; Mendiola C; Sugimoto A; D'Hondt V; Oza A; Germa JR; Roy M; Brotto L; Chen D; Eisenhauer EA
    J Natl Cancer Inst; 2010 Oct; 102(20):1547-56. PubMed ID: 20937992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer.
    van der Burg ME; Onstenk W; Boere IA; Look M; Ottevanger PB; de Gooyer D; Kerkhofs LG; Valster FA; Ruit JB; van Reisen AG; Goey SH; van der Torren AM; ten Bokkel Huinink D; Kok TC; Verweij J; van Doorn HC
    Eur J Cancer; 2014 Oct; 50(15):2592-601. PubMed ID: 25096168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of adjuvant paclitaxel and carboplatin for advanced stage epithelial ovarian cancer: a population-based cohort study of all patients in western Sweden with long-term follow-up.
    Akeson M; Zetterqvist BM; Dahllöf K; Brännström M; Horvath G
    Acta Obstet Gynecol Scand; 2008; 87(12):1343-52. PubMed ID: 18951208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A rare case of ovarian carcinosarcoma with squamous cell carcinoma.
    Daimon A; Fujiwara S; Tanaka Y; Tanaka T; Ohmichi M
    J Ovarian Res; 2019 Apr; 12(1):32. PubMed ID: 30947745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.